Advertisement

Table of Contents

Masters of Immunology

Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities

Meeting Report

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion
    Robert M. Conry, Joseph C. Sullivan and Louis B. Nabors III
    Cancer Immunol Res June 1 2015 3 (6) 598-601; DOI:10.1158/2326-6066.CIR-15-0035

    Conry and colleagues report two novel immune-related adverse events—encephalopathy with a reversible splenial lesion and neurogenic bladder—in a patient with stage IV melanoma treated with ipilimumab, which were resolved completely with high-dose methylprednisolone.

Priority Brief

  • Priority Brief
    BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
    Sherille D. Bradley, Zeming Chen, Brenda Melendez, Amjad Talukder, Jahan S. Khalili, Tania Rodriguez-Cruz, Shujuan Liu, Mayra Whittington, Wanleng Deng, Fenge Li, Chantale Bernatchez, Laszlo G. Radvanyi, Michael A. Davies, Patrick Hwu and Gregory Lizée
    Cancer Immunol Res June 1 2015 3 (6) 602-609; DOI:10.1158/2326-6066.CIR-15-0030

    Bradley, Chen, and colleagues show that BRAFV600E-induced internalization of MHC class I and its sequestration within endolysosomal compartments can be reversed by MAP kinase inhibitors, demonstrating a direct link between oncogenic activation of the MAPK pathway and MHC class I trafficking and localization.

Research Articles

  • Research Articles
    PD-1 Restrains Radiotherapy-Induced Abscopal Effect
    Sean S. Park, Haidong Dong, Xin Liu, Susan M. Harrington, Christopher J. Krco, Michael P. Grams, Aaron S. Mansfield, Keith M. Furutani, Kenneth R. Olivier and Eugene D. Kwon
    Cancer Immunol Res June 1 2015 3 (6) 610-619; DOI:10.1158/2326-6066.CIR-14-0138

    Park, Dong, and colleagues show in mouse models of melanoma and renal cell carcinoma that stereotactic ablative radiotherapy synergized with PD-1 blockade to induce near-complete regression of the irradiated tumors, and a tumor-specific 66% reduction in the nonirradiated tumors outside the radiation field.

  • Research Articles
    PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
    Jill J. Severson, Hilary S. Serracino, Valerica Mateescu, Christopher D. Raeburn, Robert C. McIntyre Jr, Sharon B. Sams, Bryan R. Haugen and Jena D. French
    Cancer Immunol Res June 1 2015 3 (6) 620-630; DOI:10.1158/2326-6066.CIR-14-0201

    Severson and colleagues show that exhaustion of PD-1+ T cells in tumor-involved lymph nodes from patients with metastatic differentiated thyroid cancer was not complete. While PD-1+CD8+ T cells were variably dysfunctional in their ability to produce cytokines, their proliferative capacity was maintained, and PD-1+CD4+ T cells remained functional.

  • Research Articles
    Robust Antitumor Effects of Combined Anti–CD4-Depleting Antibody and Anti–PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
    Satoshi Ueha, Shoji Yokochi, Yoshiro Ishiwata, Haru Ogiwara, Krishant Chand, Takuya Nakajima, Kosuke Hachiga, Shigeyuki Shichino, Yuya Terashima, Etsuko Toda, Francis H.W. Shand, Kazuhiro Kakimi, Satoru Ito and Kouji Matsushima
    Cancer Immunol Res June 1 2015 3 (6) 631-640; DOI:10.1158/2326-6066.CIR-14-0190

    Ueha, Yokochi, Ishiwata, and colleagues show in three mouse tumor models that CD4 depletion led to tumor-specific CTL proliferation in the draining lymph node and increased tumor infiltration of PD-1+CD8+ T cells; it also synergized with PD-1/PD-L1 blockade to suppress tumor growth and prolong survival.

  • Research Articles | AuthorChoice
    A Rapid Embryonic Stem Cell–Based Mouse Model for B-cell Lymphomas Driven by Epstein–Barr Virus Protein LMP1
    Zhaoqing Ba, Fei-Long Meng, Monica Gostissa, Pei-Yi Huang, Qiang Ke, Zhe Wang, Mai N. Dao, Yuko Fujiwara, Klaus Rajewsky, Baochun Zhang and Frederick W. Alt
    Cancer Immunol Res June 1 2015 3 (6) 641-649; DOI:10.1158/2326-6066.CIR-15-0058

    Ba, Meng, Gostissa, and colleagues developed an ES cell/RAG2-deficient blastocyst complementation-based model for Epstein–Barr virus protein LMP1-driven B-cell lymphomas that allows rapid analyses of genetic alterations that cooperate with LMP1 to promote lymphomagenesis and immunotherapeutic strategies.

  • Research Articles | AuthorChoice
    Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma
    Leo Hansmann, Lisa Blum, Chia-Hsin Ju, Michaela Liedtke, William H. Robinson and Mark M. Davis
    Cancer Immunol Res June 1 2015 3 (6) 650-660; DOI:10.1158/2326-6066.CIR-14-0236-T

    Hansmann and colleagues used cytometry by time-of-flight (CyTOF) and next-generation sequencing to detect cancer-associated immune phenotypes in human peripheral blood on a single-cell level, leading to identification of an expanded novel memory B-cell phenotype in multiple myeloma.

  • Research Articles
    Fine-tuning Tumor Immunity with Integrin Trans-regulation
    Joseph M. Cantor, David M. Rose, Marina Slepak and Mark H. Ginsberg
    Cancer Immunol Res June 1 2015 3 (6) 661-667; DOI:10.1158/2326-6066.CIR-13-0226

    Cantor and colleagues created an α4(S988A) integrin-bearing mouse, which precludes PKA-mediated α4 phosphorylation, and showed that manipulating the signaling properties of α4 integrins can selectively enhance T-cell entry, but not myeloid-cell entry, into B16 melanomas, thereby limiting tumor growth.

  • Research Articles
    Generation of Mouse Pluripotent Stem Cell–Derived Proliferating Myeloid Cells as an Unlimited Source of Functional Antigen-Presenting Cells
    Rong Zhang, Tian-Yi Liu, Satoru Senju, Miwa Haruta, Narumi Hirosawa, Motoharu Suzuki, Minako Tatsumi, Norihiro Ueda, Hiroyuki Maki, Ryusuke Nakatsuka, Yoshikazu Matsuoka, Yutaka Sasaki, Shinobu Tsuzuki, Hayao Nakanishi, Ryoko Araki, Masumi Abe, Yoshiki Akatsuka, Yasushi Sakamoto, Yoshiaki Sonoda, Yasuharu Nishimura, Kiyotaka Kuzushima and Yasushi Uemura
    Cancer Immunol Res June 1 2015 3 (6) 668-677; DOI:10.1158/2326-6066.CIR-14-0117

    Zhang and colleagues transduced c-Myc into mouse iPSC (induced pluripotent stem cells) to generate proliferating myeloid cells that propagate in a cytokine-dependent manner while retaining their potential to differentiate into functional antigen-presenting cells that stimulate tumor antigen-specific T-cell responses.

  • Research Articles
    Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91
    Josephine Salimu, Lisa K. Spary, Saly Al-Taei, Aled Clayton, Malcolm D. Mason, John Staffurth and Zsuzsanna Tabi
    Cancer Immunol Res June 1 2015 3 (6) 678-688; DOI:10.1158/2326-6066.CIR-14-0079

    Salimu and colleagues show that preexisting tumor antigen-specific T cells can be reactivated as a consequence of radiotherapy and demonstrate the crucial role that Hsp70, rather than TLR4, plays in antigen cross-presentation from irradiated tumor cells.

  • Research Articles | AuthorChoice
    Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
    Elizabeth E. Evans, Alan S. Jonason Jr, Holm Bussler, Sebold Torno, Janaki Veeraraghavan, Christine Reilly, Michael A. Doherty, Jennifer Seils, Laurie A. Winter, Crystal Mallow, Renee Kirk, Alan Howell, Susan Giralico, Maria Scrivens, Katya Klimatcheva, Terrence L. Fisher, William J. Bowers, Mark Paris, Ernest S. Smith and Maurice Zauderer
    Cancer Immunol Res June 1 2015 3 (6) 689-701; DOI:10.1158/2326-6066.CIR-14-0171

    Evans and colleagues describe a novel immunomodulatory function of semaphorin 4D (SEMA4D) and show that blocking SEMA4D enhances immune infiltration into tumor and increases antitumor activity in synergy with other immunomodulatory therapies.

Back to top
Cancer Immunology Research: 3 (6)
June 2015
Volume 3, Issue 6

Sign up for alerts

Jump to

Advertisement